Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology-Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3-Month Effects on Biomarkers of Bone Turnover
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Oral administration of calcitonin could improve compliance to long-term treatment. Efficacy and safety of a novel oral formulation was assessed on 277 postmenopausal women. The results show (1) effective enteral absorption, (2) marked inhibition of bone resorption with minimal alteration of formation, and (3) reproducibility of responses over 3 months. Introduction: We have recently introduced an Eligen technology-based oral formulation of salmon calcitonin (sCT) that effectively delivers the hormone to the circulation. The efficacy and safety during longer-term administration, however, has not been investigated in the target population. Materials and Methods: This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging clinical trial including 277 healthy postmenopausal women 55-85 years of age. Women received treatment with either daily (0.15, 0.4, 1.0, or 2.5 mg) or intermittent doses (1.0 mg, every other day) of sCT combined with the delivery agent (8-[N-2-hydroxi-5-chloro-benzoyl]-amino-caprylic acid, 200 mg) or placebo for 3 months. All participants received 1000 mg calcium plus 400 IU vitamin D daily throughout the study. Efficacy parameters were the acute and/or pre-dose changes in serum and urinary C-terminal telopeptide of type I collagen (CTx), N-mid osteocalcin (OC), bone-specific alkaline phosphatase (BSALP), calcium, and parathyroid hormone (PTH) measured by established immunoassays. Results: After the first dose, sCT evoked dose-dependent decreases in serum CTx (−60.8% to −81.8% from baseline) compared with placebo, reaching nadirs 2-3 h after drug intake, after which, gradual increases were observed. The simultaneous acute changes in OC were statistically nonsignificant. Area under the curve (AUC) of serum CTx responses at months 1 and 3 showed strong correlation with those at baseline (both r = 0.78, p < 0.001). At month 3, the placebo-corrected changes in the pre-dose value of serum and urinary CTx were significant only in the 1.0-mg dose group (−18.9% and −20.5%, respectively, p < 0.05). The placebo-corrected change in OC was −8.6 (p = 0.09), whereas the change in BSALP was −7.3 (p = 0.02). The oral formulation was well tolerated, with mild to moderate gastrointestinal and skin manifestations apparent mainly in the high-dose groups. Conclusion: The results of this 3-month trial show that the novel Eligen technology-based oral formulation of sCT has potential to become a safe and effective treatment for postmenopausal bone loss. Future trials are needed to assess the impact of long-term administration on changes in BMD and fracture risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Cited by
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114097 · Cited by 424
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Salmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
“A more recent 3 months’ dose ranging study in 277 postmenopausal women confirmed the effective absorption from the gastrointestinal tract, resulting in dose-dependent, sustained responses in bone resorption markers [102].”
BackgroundSelf-citationChesnut, C. H., Majumdar, S., Newitt, D. C., Shields, A., Van Pelt, J., Laschansky, E., Azria, M., Kriegman, A., Olson, M., Eriksen, E. F., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050411 · Cited by 163
Self-citationSafety concerns over the use of intestinal permeation enhancers: A mini-review
McCartney, F., Gleeson, J. P., & Brayden, D. J. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1176822 · Cited by 156
Metadata
- Authors
- Tankó, L. B., Bagger, Y. Z., Alexandersen, P., Devogelaer, J.-P., Reginster, J.-Y., Chick, R., Olson, M., Benmammar, H., Mindeholm, L., Azria, M., & Christiansen, C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 19
- Issue
- 9
- Pages
- 1531-1538
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1980139145
- Cited by
- 94
- References
- 1
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.